INTRODUCTION
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder that is associated with the presence of the Philadelphia chromosome carrying the chimeric BCR-ABL oncogenes, which is generated by a reciprocal translocation between chromosomes 9 and 22, t (9;22) . 1, 2 This translocation causes the fusion of two normal genes, the 5 0 -portion of the BCR gene in chromosome 22 and the 3 0 -portion of the ABL gene in chromosome 9. 3 The ABL gene, present in all tissues, encodes for a nonreceptor tyrosine kinase (TK) that has an important role in signal transduction and the regulation of cell growth. However, little is known about the function of the BCR protein translated from the BCR gene. 2 BCR-ABL mRNA contains two types of possible junctions, b3a2 (composed of BCR exon 3 and ABL exon 2) and b2a2 (composed of BCR exon 2 and ABL exon 2). 4, 5 Both of these mRNAs encode for a protein of 210 kDa (p210 BCR/ABL ), which is localized in the cytoplasm and which exhibits constitutively activated TK activity, leading to uncontrolled cell proliferation with a reduced apoptotic response to mutagenic stimuli. 6 The BCR-ABL TK expressed in cells has been shown to mitigate surveillance of the G 1 -S phase transition, thereby enhancing cell proliferation. 7 In particular, BCR-ABL inhibits the activity of the Cdk inhibitor p21 and decreases p27 expression, both of which are involved in important checkpoints for the G 1 -S phase transition. 8, 9 In addition, it has been shown that expression of p210 BCR/ABL bestows resistance to apoptosis by delaying upstream procaspase-3 activation in transforming cells. 10 Imatinib mesylate, a competitive inhibitor that binds to the ATP-binding site of BCR-ABL, is an antileukemic drug that was developed as a targeted therapy against the chimeric BCR-ABL TK and is currently considered a first-line agent for newly diagnosed CML. [11] [12] [13] However, despite its impressive efficacy, disease relapse has been observed after initial response to imatinib. 14, 15 Drug resistance during imatinib treatment is mostly related to point mutations occurring within the kinase domain of BCR-ABL at more than 40 different amino acid positions. 16 These point mutations may either disrupt interactions between imatinib and BCR-ABL or prevent the kinase from converting into the inactive conformation. 17 To overcome this challenge, dasatinib, a SRC (sarcoma)-family TK inhibitor, was developed; dasatinib shows a broader spectrum of activity against many mutant forms of BCR-ABL. 14, 18 Despite this, the T315I mutant of BCR-ABL has been reported to show resistance to both imatinib and dasatinib. 11 The T315I mutant contains a single-base change (C to U) in the ABL gene, leading to replacement of the threonine (T) at position 315 with an isoleucine (I). Mutations occurring in the 'gatekeeper' or contact region (for example, T315I) of the BCR-ABL kinase are known to cause resistance to most kinase inhibitors, including imatinib, nilotinib, dasatinib and bosutinib. 19 Thus, novel and more effective therapeutic alternatives are needed to overcome this ability of mutant kinases to evade the effects of current BCR-ABL kinase inhibitors used in CML patients.
RNA-cleaving deoxyribozyme (DNAzyme), which is capable of sequence-specific cleavage of target mRNA, was discovered through in vitro selection technology. 20 The '10-23' RNAcleaving DNAzyme can recognize RNA through the WatsonCrick base pairing and can cleave its target at a phosphodiester bond located between an unpaired purine (R) and pyrimidine (Y) (box in Figure 1 ). DNAzymes that target the BCR-ABL chimeric mRNA junction sequence have been developed, and their efficacy toward target RNA cleavage has been tested. 21, 22 In addition to DNAzymes, there have been several attempts to suppress the expression of BCR-ABL with antisense DNA, 23, 24 ribozymes, 22 siRNA, 25, 26 peptide nucleic acid, 27 and locked nucleic acid. 28 All of these antisense molecules are directed against BCR-ABL junctions, not the drug-resistant mutants occurring in the ABL gene.
In this study, we designed DNAzymes that specifically target and cleave the junction sequence and/or the site of point mutation conferring T315I drug resistance in BCR-ABL mRNA. The designed DNAzymes were introduced into cells harboring the BCR-ABL gene with or without the T315I mutation, and we investigated the ability of these DNAzymes to inhibit the expression of BCR-ABL and to restore imatinib sensitivity in cells harboring the drug-resistant leukemogenic gene.
MATERIALS AND METHODS

Oligonucleotides and reagents
The 10-23 oligodeoxyribozymes (shown in Figure 1 ) and DNA templates for BCR-ABL substrate RNA and for both wild-type and mutant ABL substrate RNAs were chemically synthesized (Cosmo Gentech, Seoul, Korea). DNA templates harbored the antisense sequence of the T7 promoter and the respective RNA sequence for the in vitro synthesis of RNAs using the T7 RNA polymerase. 29 In vitro synthesis of RNAs was performed as described previously. 30 Imatinib mesylate STI571 (Gleevec) was kindly provided by Novartis, Inc. (Basel, Switzerland). Imatinib stock solution (10 mg/ml) was prepared by dissolving the compound in dimethylsulfoxide:H 2 O (1:1) and was then stored at À 20 1C.
RNA cleavage with DNAzymes
Substrate RNAs were labeled using T4 polynucleotide kinase and [g-32 P]ATP (6000 Ci/mmol, GE Healthcare, Piscataway, NJ, USA). Target RNA cleavage activities of DNAzymes were tested in reaction buffer (10 mM MgCl 2 and 20 mM Tris-HCl, pH 7.5) at 37 1C. The reaction was initiated by combining a trace amount of 32 P-5 0 -labeled substrate RNA, mixed with each unlabeled corresponding substrate (to yield a final concentration of 100 nM RNA), and DNAzyme (1 mM final concentration). The 20-ml reaction mixture was incubated for 3 h and quenched by adding an equal volume of the gel-loading dye containing 25 mM Na 2 EDTA and 8 M urea. The products were resolved by 12% (w/v) denaturing polyacrylamide gel electrophoresis, and the product bands were visualized and quantified on a Cyclone PhosphorImager (Packard Instruments, Meriden, CT, USA).
Cell culture, DNAzyme transfection and drug administration BaF3 cells, a mouse pro-B cell line that is stably transduced with BCR-ABL (BaF3/BCR-ABL) or drug-resistant mutant BCR-ABL T315I (BaF3/ BCR-ABL T315I ), were cultured in RPMI 1640 media containing 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin at 37 1C under 5% CO 2 . Chemically synthesized DNAzymes were transfected into the cells by electroporation using the Neon Transfection System (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. T315I DNAzyme, BP DNAzyme and BP-T315I tandem DNAzyme were used at concentrations of 4 mg (T315I and BP DNAzyme) and 10 mg (tandem DNAzyme) per 5 Â 10 5 cells and electroporated at 1100 V with a double pulse (30 ms pulse width). Following electroporation, cells were resuspended in RPMI medium and further incubated at 37 1C for the designated times (usually 48 h). Percentage of cells transfected with the oligo DNA was estimated to be about 80% when the electroporation is applied to the cells (Supplementary Figure S1) .
Western blotting and quantitative real-time reverse-transcription PCR Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1.0% NP40, 1 mM phenylmethanesulfonylfluoride) for 1 h on ice. A total of 30 mg of protein was separated by gradient SDSpolyacrylamide gel electrophoresis (4-12% polyacrylamide). Proteins were then transferred to a nitrocellulose membrane (Whatman) and the membrane was immunoblotted with anti-c-ABL monoclonal (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-b-actin antibodies (1:1500; Santa Cruz Biotechnology). The membrane was subsequently incubated with horseradish peroxidase-conjugated anti-goat immunoglobulin, and signals were detected with an enhanced chemiluminescence system (Intron Biotechnology, Seoul, Korea). RNA isolation for reverse transcription of ABL mRNA was carried out as described. 31 Primers for amplification of T315I ABL transcripts were designed as follows: forward primer 5 0 -GCC CCC GTT CTA TAT CAT CAT TGA-3 0 (the point mutation conferring the T315I mutation is underlined); reverse primer 5 0 -TGG ATG AAG TTT TTC TTC TCC AG-3 0 . For quantitative real-time PCR, the T315I Figure 1 . Sequences of the DNAzymes targeting BCR-ABL chimeric mRNA. The sequence of BCR-ABL near the junction between the BCR exon (b3) and ABL exon (a2) is shown. The T315I point mutation (C to U) is indicated in the ABL exon. Potential sites of cleavage by the constructed DNAzymes are indicated by arrows.
ABL cDNA was amplified using the SYBR Green Premix Ex Taq Kit (TaKaRa, Shiga, Japan 
RESULTS
Design of DNAzymes targeting BCR-ABL RNA harboring the T315I point mutation
In previous studies, several antisense nucleic acids directed against the junction of two noncontiguous sequences of BCR and ABL exons were designed and tested for their ability to discriminate between the chimeric RNA substrate and the nontarget sequences. 21, 22, 32 Among these antisense nucleic acids, we chose a DNAzyme (BP DNAzyme in Figure 1 ) as a positive control for the cleavage of the RNA substrate; this DNAzyme has been reported to cleave the BCR-ABL junction of the b3a2 splice variant. 21 The cleavage site for BP DNAzyme is located 5 nucleotides (nts) upstream from the fusion site for b3a2. Next we set out to design a DNAzyme that could cleave ABL exon RNA harboring the T315I point mutation. As DNAzymes can distinguish single-base mismatches near the cleavage site in RNA when complexed with substrate RNA, a target site for DNAzyme was chosen to specifically cleave only T315I-mutant RNA ( Figure 1 ). As shown in Figure 1 , the DNAzyme termed T315I DNAzyme was designed to cleave the phosphodiester bond between A and U, not affecting the A-C bond at the same site in the wild-type ABL exon. An adenine base was incorporated in the 5 0 -hybridizing arm of the designed DNAzyme to specifically recognize the mutant base (U) in the cleavage site (boxed base pair in the T315I DNAzyme, Figure 1 ). We also designed a tandem DNAzyme that combined BP DNAzyme and T315I DNAzyme with oligo dT(18) spacing nts ( Figure 1 ). This tandem DNAzyme was expected to cleave both the BCR-ABL junction and the T315I point mutation in the BCR-ABL mutant mRNA.
Specific cleavage of ABL RNA containing the T315I point mutation To examine the specificity of RNA cleavage by the designed DNAzyme, we investigated its RNA-cleavage activity and specificity using short RNA substrates, such as chimeric BCR-ABL RNA, wild-type ABL RNA and mutant ABL T315I RNA (Figure 2a ). Substrate BCR-ABL chimeric RNA consisted of the sequence from 19 nts 5 0 of the BCR-ABL breakpoint (b3a2 exon junction) to 20 nts 3 0 of the BCR-ABL junction. The part of the ABL exon (a2) harboring the T315I point mutation (C to U) was chosen as the RNA substrate (45 nts) for T315I DNAzyme, and the corresponding wild-type ABL RNA was also prepared as a control RNA substrate. BP DNAzyme exhibited high specificity, cleaving only chimeric BCR-ABL RNA (Figure 2b ). When T315I DNAzyme was incubated with mutant ABL RNA (ABL T315I ), RNA cleavage was clearly observed (Figure 2b ). In contrast, no RNA-cleavage activity toward the wild-type ABL RNA substrate was observed with both DNAzymes. We further tested the RNA-cleavage activity of the tandem DNAzyme, which was designed to cleave both the BCR-ABL breakpoint and the T315I point mutation. This tandem DNAzyme cleaved the RNA substrates of both BCR-ABL and ABL T315I with similar efficiency (Figure 2c ). When the two RNA substrates (BCR-ABL and ABL T315I ) were mixed together in the reaction, the tandem DNAzyme cleaved both RNA substrates. The efficiency of RNA cleavage with the tandem DNAzyme was comparable to that achieved when the two separate DNAzymes were added to the reaction (Figure 2c ).
Cleavage of ABL transcripts reduced ABL expression and cell viability To demonstrate whether cleavage of mutant ABL RNA with the DNAzyme could reduce expression of the ABL gene and subsequently decrease the viability of cells containing the BCR-ABL gene, we tested the efficacy of the DNAzymes in leukemic cells. BaF3 cells that stably expressed BCR-ABL or mutant BCR-ABL T315I were electroporated with DNAzymes targeting either the BCR-ABL breakpoint (BP Dz) or the T315I mutant base (T315I Dz). The tandem DNAzyme composed of the two DNAzymes was also transfected into the cells. A DNAzyme targeting a scrambled sequence was also used as a control to assess nonspecific effects of oligonucleotide transfection. Figure 3a shows the amount of remaining ABL T315I RNA transcript upon treatment with T315I DNAzyme in BaF3 cells, in which wildtype (BaF3/BCR-ABL) cells were mixed with imatinib-resistant (BaF3/BCR-ABL T315I ) cells in different ratios. When T315I DNAzyme was transfected into BaF3/BCR-ABL T315I cells, about 50% of ABL T315I mRNA was degraded by 48 h, as demonstrated by real-time PCR. However, transfection with T315I DNAzyme did not decrease the amount of ABL mRNA in BaF3/BCR-ABL cells, indicating that T315I DNAzyme specifically cleaves the T315I point mutation present in ABL T315I RNA in BaF3/BCR-ABL T315I cells.
The specificity of DNAzymes against the target was also demonstrated by reduced expression of ABL proteins. As shown in Figure 3b , treatment with each DNAzyme targeting BCR-ABL led to decreased expression of BCR-ABL protein. Imatinib treatment did not decrease the expression of BCR-ABL protein, but treatment with BP DNAzyme significantly reduced the expression of BCR-ABL in the cells. As expected, T315I DNAzyme was more effective at reducing BCR-ABL T315I expression in imatinib-resistant cells than in imatinib-sensitive BCR-ABL cells. However, BP DNAzyme was effective at inhibiting the expression of BCR-ABL in both wild-type and mutant cells. The decrease of BCR-ABL with tandem DNAzyme treatment was similar to that observed with the T315I DNAzyme, suggesting that the efficacy of T315I-mutant RNA cleavage was not compromised by the fusion of these two DNAzymes. In contrast, tandem DNAzyme was not as effective as BP Dz in suppressing the expression of BCR-ABL in wild-type cells. These results are likely caused by an inequality of tandem DNAzyme in binding of two target sites on the full length BCR-ABL mRNA containing the T315I mutation in cytoplasm.
We next determined how cell proliferation was affected by silencing BCR-ABL or the ABL T315I mutant in leukemic cells. BaF3 cells expressing either BCR-ABL or BCR-ABL T315I were treated with each DNAzyme (BP Dz or T315I Dz) twice at intervals of 24 h. The cells were also treated with the tandem DNAzyme targeting both the breakpoint and the T315I mutant base. As expected, imatinib treatment decreased the viability of BaF3/BCR-ABL cells, but not BaF3 cells containing the ABL T315I mutation (Figure 3c ). Treatment with BP Dz reduced cell viability by about 30% in both cell lines, whereas treatment with T315I Dz significantly reduced the viability of drug-resistant cells by more than 50%, but did not affect BaF3 cells expressing BCR-ABL (Figure 3c) . Interestingly, the tandem DNAzyme was more effective at reducing the viability of imatinib-resistant cells than of BaF3 cells lacking the T315I mutation. This result can be explained by the inequality of tandem DNAzyme in binding of two target sites in cytoplasm. Treatment with both imatinib and DNAzyme led to a significant reduction in the viability of BaF3/ BCR-ABL cells, which was not observed with single treatment of either DNAzyme (Figure 3c ). This result suggests that imatinib treatment was more effective than DNAzyme treatment in reducing the viability of BCR-ABL-positive cells. In contrast, the viability of imatinib-resistant cells was mainly determined by DNAzyme activity when combined treatment of DNAzyme and imatinib was applied to the cells.
In addition, we investigated cell growth rate of the leukemic cells that were incubated up to 24 h after treatment with each DNAzyme Figure S2) . Consistent with the result shown in Figure 3c , T315I Dz was the most potent in reducing growth rate of the imatinib-resistant BCR-ABL cells. In contrast, the imatinib-sensitive BCR-ABL cells were more susceptible to cell death with BP Dz than with T315I Dz. BP Dz treatment reduced cell growth rate of both cells that contain BCR-ABL junction (BaF3/BCR-ABL and BaF3/BCR-ABL T315I ). When the cell viability was measured at 72 h after transfection of DNAzyme (Supplementary Figure S3) , BP Dz treatment reduced the cell viability in both cells that contain BCR-ABL junction (BaF3/BCR-ABL and BaF3/BCR-ABL T315I ) to a similar extent. In contrast, T315I Dz prolonged its efficacy preferably against the imatinib-resistant cells (BaF3/BCR-ABL T315I ) for 72 h, resulting in a decrease of cell viability up to 25%.
Imatinib resistance was lost by cleaving mutant ABL transcripts with T315I DNAzyme To further investigate the biological consequences of DNAzyme treatment on leukemic cells expressing BCR-ABL or BCR-ABL T315I , the cells were transfected with each DNAzyme and analyzed for apoptosis. As increased apoptosis may result from DNA fragmentation that can be caused by electroporation, a mock transfection was performed to assess the background level of apoptotic cells. In both BaF3/BCR-ABL and BaF3/BCR-ABL T315I cells, electroporation caused only a small increase in the apoptotic cell population (less than 5% of the total cells; see controls in Figure 4 ). When imatinib-resistant BCR-ABL cells were treated with the DNAzyme targeting the T315I mutant (T315I Dz), a significant increase in the apoptotic cell population, by about 90%, was observed (Figures 4a  and c) . In contrast, the DNAzyme targeting the BCR-ABL junction (BP Dz) was not effective at enhancing the apoptosis of BCR-ABL Figure 2 . Specificity of the constructed DNAzymes in target RNA cleavage. (a) Three RNA substrates were used to examine the specificity of the DNAzymes toward target RNA cleavage. For efficient RNA synthesis by the T7 RNA polymerase, two G nucleotides were introduced at the 5 0 -end of ABL and BCR-ABL RNAs. P* represents the 5 0 -end labeling of the radioactive phosphate. The T315I point mutation is indicated as a boxed base. (b) Each DNA enzyme (1 mM) and 100 nM 5 0 -32 P-labeled substrate were incubated at 37 1C for 60 min in a solution that contained 20 mM Tris-HCl (pH 7.5) and 10 mM MgCl 2 , and reactions were then subjected to electrophoresis on 10% polyacrylamide/8 M urea gels. BP DNAzyme generated a 19-nt 5 0 -fragment of cleaved RNA. Cleavage of mutant ABL RNA (ABL T315I ) substrate by T315I DNAzyme generated a 5 0 -fragment of 23 nts. A DNAzyme targeting a scrambled sequence was also used as a control (lane C). (c) The tandem DNAzyme (1 mM) cleaved both BCR-ABL RNA and mutant ABL T315I RNA (100 nM substrate). The right panel shows that mixed RNA substrates (100 nM each) were present in the RNA cleavage reaction. Similar to the tandem DNAzyme, the mixture of BP DNAzyme and T315I DNAzyme cleaved both BCR-ABL RNA and mutant ABL T315I RNA. leukemic cells after 48 h. Moreover, the tandem DNAzyme was less effective than the T315I DNAzyme alone at inducing apoptosis in imatinib-resistant BCR-ABL cells. Although the tandem DNAzyme was efficient at cleaving the target RNA at both sites in vitro, this DNAzyme may not be able to simultaneously bind to two separate target sites (BP and T315I) in cells because of the long intervening stretch of mRNA between the two target sites.
Next, we further tested whether the cleavage of BCR-ABL transcripts by DNAzyme was sufficient to overcome imatinib resistance. For analysis of apoptosis resulting from the combined use of DNAzymes and imatinib, we used suboptimal amounts of imatinib (1 mM). Expression of the BCR-ABL T315I kinase in BaF3 cells conferred strong resistance to imatinib, whereas cells with nonmutated BCR-ABL were sensitive to imatinib treatment (Figure 4b ). Treatment with imatinib and T315I DNAzyme together in BaF3/BCR-ABL T315I cells increased the frequency of apoptosis in leukemic cells by 77.3% as compared with single treatment with imatinib alone (Figures 4b and c) . Thus, T315I DNAzyme restored imatinib sensitivity in BaF3/BCR-ABL T315I cells, causing apoptosis in about 80% of the cells.
We further examined the effects of DNAzymes on BCR-ABL-positive human cells (K562 cells) and primary cell lines (bone marrow cells) derived from the imatinib-resistant BCR-ABLpositive leukemia patients. When the imatinib-sensitive BCR-ABL-positive K562 cells were treated with imatinib or BP Dz that cleaves the BCR-ABL junction, the cells exhibited a significant increase in apoptotic cell death by about 40B50% as compared with the control (Supplementary Figure S4a) . In contrast, T315I Dz (25%) was more effective than BP Dz (8.7%) in enhancing apoptosis of the primary cells from imatinib-resistant BCR-ABLpositive leukemia patients (Supplementary Figure S4b) . Combined use of T315I Dz and imatinib further increased apoptotic cell deaths in the primary cells. These data are consistent with the results obtained with BaF3 cells, in which T315I Dz was effective in reducing cell viability of the imatinib-resistant BCR-ABL-positive leukemic cells.
Combined use of imatinib and T315I DNAzyme causes cell cycle arrest and activation of apoptotic caspases in imatinib-resistant leukemic cells
We next investigated the influence of DNAzymes and imatinib on the cell cycle by analyzing the relative distribution of cells in G 1 , S, G 2 and sub-G 1 phases. At 24 h after DNAzyme transfection and imatinib treatment, cells expressing BCR-ABL or BCR-ABL T315I were collected, and cell cycle distribution was analyzed by fluorescence-activated cell sorting. In BaF3/BCR-ABL cells, the majority of cells treated with imatinib alone (58.7%) or with imatinib and T315I DNAzyme together (59.6%) were found in the apoptotic sub-G 1 phase, whereas single treatment with T315I DNAzyme or the tandem DNAzyme did not affect cell cycle progression ( Figure 5 ). In contrast, in BaF3/BCR-ABL T315I cells, treatment with T315I DNAzyme alone or with a combination of T315I DNAzyme and imatinib significantly enhanced apoptotic sub-G 1 populations to 46% and 70% of total cells, respectively. Therefore, T315I DNAzyme was more effective at arresting cell cycle progression in imatinib-resistant cells (BaF3/BCR-ABL T315I ) than in BaF3/BCR-ABL cells.
Next, to confirm the dependence of DNAzyme-induced cell death in BCR-ABL-positive leukemic cells on caspase activity, we examined whether treatment with T315I DNAzyme induced apoptosis through activation of caspase-3 and caspase-7. Leukemic cells with or without the T315I mutation were transfected with three DNAzymes, BP Dz, T315I Dz or tandem Dz, for 24 h. Induction of caspase-3/-7 activity was then measured by the appearance of luminescent products generated by the activity of caspase-3/7 ( Figure 6 ). For a positive control, staurosporine (an inhibitor of phospholipid/calcium-dependent protein kinase), which has been shown to induce apoptosis by caspase activation in a variety of cell types, was used. Staurosporine treatment resulted in induction of caspase-3/-7 activity in both cell types. Treatment with BP DNAzyme significantly induced the activation of caspases-3/-7 in BaF3/BCR-ABL cells, and this effect was more pronounced with the addition of imatinib (Figure 6a ). In contrast, the relative increase in caspase-3/-7 activity observed in imatinib-resistant cells (BaF3/BCR-ABL T315I ) treated with T315I DNAzyme was greater than that observed in BaF3/BCR-ABL cells treated with the same DNAzyme (Figure 6b ).
More importantly, induction of caspase-3/-7 activity was greatly enhanced by combined treatment with T315I DNAzyme and imatinib in BaF3/BCR-ABL T315I cells. Several studies suggest a role of imatinib on phosphatidylinositol-3 kinase/AKT signaling pathway by inhibiting AKT phosphorylation at Ser473 position in cancer cells. [33] [34] [35] [36] [37] We observed that imatinib treatment resulted in a significant dose-responsive reduction in the AKT phosphorylation at position Ser473 in the imatinib-resistant cells (Supplementary Figure S5) . Thus, the synergistic inhibitory effect by combined treatment of T315I Dz and imatinib has probably resulted from combined efficacies of two different inhibitors, T315I DNAzyme and imatinib against BCR-ABL T315I mRNA and phosphatidylinositol-3 kinase/AKT signaling pathway, respectively. responses, patients with BCR-ABL-positive leukemia tend to develop resistance to imatinib and second-generation agents. 38 This drug resistance is often caused by mutations in the gatekeeper region (for example, T315I and F317L) of the BCR-ABL kinase, which disrupt critical contact points between imatinib and BCR-ABL, conferring imatinib resistance to the affected cells. 39 The T315I mutation in BCR-ABL is the main cause of imatinib resistance in CML patients, and the prognosis of CML patients resistant to imatinib because of this mutation is poor in terms of survival. Specific silencing of the chimeric BCR-ABL gene by siRNA has been used to downregulate the expression of leukemogenic BCR-ABL. Scherr et al. 26 demonstrated that siRNA targeting the breakpoint in BCR-ABL fusion RNA interfered with the induction of BCR-ABL expression in BCR-ABL-positive cell lines. Use of siRNA directed against the breakpoint in the BCR-ABL fusion site b3a2 specifically downregulated the BCR-ABL protein, with a significant reduction in cell viability. Using a breakpoint-specific siRNA in BCR-ABL-positive cells, Wohlbold et al. 25 found that siRNA targeting the breakpoint of chimeric BCR-ABL RNA partially restored imatinib sensitivity, with a fourfold sensitization in cells expressing the imatinib-resistant BCR-ABL kinase domain mutant H396P, which makes leukemic cells fivefold less sensitive to imatinib compared with wild-type cells. However, they failed to reverse the high imatinib resistance of leukemic cells harboring the T315I mutation, which confers complete resistance to imatinib treatment, by siRNA targeting the breakpoint of the BCR-ABL fusion site.
DISCUSSION
Recently, Koldehoff et al. 40 reported that coadministration of a breakpoint-specific siRNA with imatinib or nilotinib resulted in enhanced inhibition of cell growth and BCR-ABL gene expression in BCR-ABL-expressing cells harboring the T315I mutation. This finding is consistent with our result that transfection with breakpoint-specific BP DNAzyme increased the activity of apoptotic executioner caspases, caspase-3 and caspase-7, in imatinib-resistant BCR-ABL cell lines (Figure 6b ). However, our strategy used in this study to directly cleave ABL RNA at the T315I point mutation site provided enhanced efficacy toward sensitization of imatinib-resistant BCR-ABL cell lines to imatinib treatment. To the best of our knowledge, cleavage of T315I-mutant ABL RNA with DNAzyme transfected into BCR-ABL-positive cells has not previously been reported as a potential method to restore imatinib sensitivity in leukemic cells. Thus, to augment the efficacy of imatinib treatment in BCR-ABL-positive cells, specific targeting of the T315I mutant site would be more effective than targeting of the breakpoint in the BCR-ABL fusion site when using antisense oligonucleotides. The use of siRNA or DNAzyme mixtures targeting both of these sites together may result in greater efficacy at restoring imatinib sensitivity. Clinically, both BCR-ABL and T315I silencing approaches may be of great relevance to the conversion of acute or blast crisis phases back to chronic phase leukemia without concerns of imatinib resistance. To this end, long-term expression of gene silencing short hairpin RNAs targeting these sites could be conducted using lentivirus vectors in BCR-ABL-positive cells.
Previous reports have demonstrated that silencing of BCR-ABL expression induces a profound defect in proliferation through decreased expression of cyclin D. 41 This result is consistent with our findings that mutant RNA cleavage by T315I DNAzyme triggered cell cycle arrest during the G 1 phase of the cell cycle in imatinib-resistant leukemia cells ( Figure 5 ). BCR-ABL T315I -transformed cells actively undergo cell proliferation without much cell death under imatinib treatment. However, combined use of the T315I DNAzyme and imatinib induced cell cycle arrest at the sub-G 1 phase in up to 70% of total cells through inhibition of mutant BCR-ABL expression and restoration of imatinib sensitivity ( Figure 5 ). We also observed that selective cleavage of the T315I mutation in ABL mRNA triggered apoptosis with activation of caspase-3/-7 in imatinib-resistant leukemic cells (Figure 6b ). This result indicated that apoptosis was related to decreased BCR-ABL expression in terms of kinase activity and/or its interacting partners. 42 It has been previously reported that ectopic expression of cyclin D1 inhibits imatinib-induced apoptosis and erythrocyte differentiation in leukemic K562 cells. 43 Thus, cell cycle arrest and apoptotic cell death caused by cleavage of mutant ABL mRNA suggests a putative interaction between BCR-ABL and cyclin D1 to maintain BCR-ABL-positive cells in a state of continuous cell cycle and differentiation block.
The specific recognition and cleavage of the target sequence by DNAzyme may be useful properties for nucleic acid-based drugs, such as antisense oligonucleotides, siRNA and ribozymes. However, as with other nucleic acid-based applications in vivo, the delivery of DNAzyme to target cells remains a considerable challenge for in vivo applications. 44 There are several approaches to introduce DNAzymes into cells, including drug-delivery systems, in which chemically synthesized DNAzymes are complexed with nanoparticles and delivered to target cells. 45, 46 Another way to introduce DNAzymes into cells is through electroporation, as used in our study. 47 This approach is limited primarily by the necessity for ex vivo manipulations of leukemic cells, in which target cells must be removed from the body, engineered and returned. 48 General advantages and disadvantages of DNAzymes have been compared with other nucleic acid-based approaches, such as ribozymes, antisense oligonucleotides and RNA interference for silencing of target gene expression. 44 Compared with these other approaches, DNAzymes are superior for potential in vivo applications, as they do not suffer from mRNA degradation and exhibit improved chemical and biological stability over RNA and protein agents. Such stability can be further enhanced through chemical modifications of DNA. In addition, unlike RNA interference DNAzymes are catalytically independent of cellular machinery and, therefore, may have the potential for rational modulation of RNA-cleavage activity. Despite these advantages of DNAzymes, proper folding of the DNAzyme, which may not be guaranteed in vivo due to lower physiological concentrations (usually less than 1 mM) 49 of Mg 2 þ than required for optimal catalytic activity of DNAzymes in vitro (10-100 mM), 20 still prove to be a challenge.
In summary, we demonstrated that RNA-cleaving DNAzymes are complementary to the imatinib-resistant point mutation (T315I) in ABL mRNA and can induce target-specific cleavage of mutant ABL mRNA. When T315I DNAzyme was transfected into imatinib-resistant BaF3/BCR-ABL T315I cells, expression of the mutant BCR-ABL kinase was downregulated. DNAzyme treatment led to inhibition of cell proliferation, accompanied by a strong induction of apoptotic cell death. A major finding of our study was that cleavage of T315I mutant RNA sensitized imatinib-resistant leukemic cells to imatinib treatment, resulting in apoptosis through activation of executioner caspases. These results suggest that the combined use of the T315I DNAzyme with imatinib may be the most effective tool to treat imatinib-resistant BCR-ABLpositive leukemic cells for ex vivo manipulations. If the DNAzyme is to be used for ex vivo gene therapy, bone marrow cells derived from the patient would be manipulated to be free of mutant BCR-ABL RNA with DNAzymes and/or imatinib, and the cells can be subsequently re-entered into the patient's bone marrow without need of the bone marrow transplantation. Although DNAzymes that have been proved to cleave RNA in vitro are now progressing toward clinical tests, they must be combined with a safe and appropriate delivery vehicles for clinical use in vivo. If combined with an effective tool to deliver the DNAzymes to cells and tissues, selective interventions in leukemic cell gene regulation by DNAzymes may be feasible for the treatment of drugresistant leukemia, such as BCR-ABL-positive CML harboring the T315I mutation.
